1. Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes
- Author
-
H. Atkins, J. Platts, Mayank Patel, Dinesh Nagi, R. Stewart, Parth Narendran, Alistair N Lumb, D. Voigt, Philip Newland-Jones, Gerry Rayman, C. Cottrell, E. Page, Brian Kennon, O. Burr, H. Courtney, Stephen Thomas, Ketan Dhatariya, Partha Kar, and Kath Higgins
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Letter ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Endocrinology, Diabetes and Metabolism ,Insulin, Isophane ,030209 endocrinology & metabolism ,Comorbidity ,Glycemic Control ,Dexamethasone ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Oxygen therapy ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Internal Medicine ,Humans ,030212 general & internal medicine ,Letters ,business.industry ,SARS-CoV-2 ,Insulin ,COVID-19 ,medicine.disease ,Hypoglycemia ,COVID-19 Drug Treatment ,business ,medicine.drug - Abstract
The RECOVERY (Randomised Evaluation of COVid‐19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one‐third in ventilated patients and by one‐fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.
- Published
- 2020
- Full Text
- View/download PDF